Nebenwirkungen · Betmiga
Betmiga 25 mg prolonged-release tablets Betmiga 50 mg prolonged-release tablets · Abschnitt 4.8 · PDF-Seite 8–9
HOS-125594 · Präparat HOS-096097
8 MedDRA Common Uncommon Rare Very rare Not known System organ (cannot be class estimated from the available data) Infections and Urinary tract Vaginal infection infestations infection Cystitis Psychiatric Insomnia* disorders Confusional state* Nervous system Headache* disorders Dizziness* Eye disorders Eyelid oedema Cardiac Tachycardia Palpitation disorders Atrial fibrillation Vascular Hypertensive disorders crisis* Gastrointestinal Nausea* Dyspepsia Lip oedema disorders Constipation* Gastritis Diarrhoea* Hepatobiliary GGT increased disorders AST increased ALT increased Skin and Urticaria Leukocytoclastic subcutaneous Rash vasculitis tissue disorders Rash macular Purpura Rash papular Angioedema* Pruritus Musculoskeletal Joint swelling and connective tissue disorders Renal and Urinary urinary retention* disorders Reproductive Vulvovaginal system and pruritus breast disorders Investigations Blood pressure increased
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T15:00:59Z · SHA-256 558bb9d8a6fe7ed39b4c0f0949d9a92ad4ac9abd83d84e765873084c7eafe957 · Passage 7792fa54559d213f24bb260f6c4766a53b96a2503414c5d9efc1febfb19c56cb · Zeichen 1969–4440 im Abschnitt